The FDA has granted accelerated approval for a new Tzield indication in children ages 8 to 17 who have recently been diagnosed with Stage 3 type 1 diabetes.
The approval is important, but it needs careful wording. Tzield is not a cure for type 1 diabetes. It does not replace insulin. The new indication is to delay the decline of the body’s own insulin production in certain children who already have Stage 3 disease.
Key takeaways
- FDA granted accelerated approval on June 12, 2026, and announced it on June 15, 2026.
- The new indication is for pediatric patients ages 8 through 17 years who were recently diagnosed with Stage 3 type 1 diabetes.
- The goal is to delay the decline of endogenous insulin production, meaning the insulin the body still makes.
- Stage 3 type 1 diabetes means symptoms are present and insulin therapy is required to manage blood glucose.
- The approval is based on C-peptide, a marker of the body’s own insulin production, and a required postapproval study is ongoing.
What changed
Tzield, also known as teplizumab or teplizumab-mzwv, was already approved to delay the onset of Stage 3 type 1 diabetes in people with Stage 2 disease. This new FDA action is different. It applies to certain children and teenagers who have already been recently diagnosed with Stage 3 type 1 diabetes.
FDA describes this as the first approved treatment for this specific pediatric Stage 3 indication. The purpose is to help slow the loss of remaining beta-cell function, not to reverse type 1 diabetes or remove the need for insulin.
The treatment schedule can differ by indication. Families may see older information about a 14-day course for the Stage 2 indication. FDA’s public summary for the new pediatric Stage 3 study describes two 12-day IV treatment courses.
Why Stage 3 matters
Type 1 diabetes is commonly described in stages. In Stage 1, a person has type 1 diabetes autoantibodies but normal blood sugar. In Stage 2, autoantibodies are still present and blood sugar has become abnormal, often before obvious symptoms.
Stage 3 is when symptoms related to high blood sugar begin, such as frequent urination, excessive thirst and fatigue. At this stage, FDA says the patient requires insulin therapy to manage blood glucose.
What evidence supported approval
The FDA public drug summary describes the PROTECT Study, a randomized, double-blind, placebo-controlled trial in 328 children and teenagers ages 8 to 17. Participants had been diagnosed with Stage 3 type 1 diabetes within the past six weeks and still had working insulin-producing beta cells at enrollment.
The study measured C-peptide at 78 weeks, or about 18 months. C-peptide is used as an indicator of how much insulin the body is still producing. FDA says patients who received teplizumab had a significantly smaller decline in beta-cell function compared with those who received placebo.
This was an accelerated approval. FDA says the approval was based on a statistically significant effect on C-peptide as a surrogate endpoint that is reasonably likely to predict clinical benefit. A required postapproval study is ongoing to verify clinical benefit.
How treatment was studied
In the FDA summary of the PROTECT Study, patients received treatment once daily through an IV for 12 days, followed by another 12-day course of treatment about six months later, at Week 26 of the study. Families should follow the prescribing information and the child’s diabetes specialist’s plan, because dosing and monitoring details belong in specialist care.
Important safety information
Tzield has a boxed warning. FDA says serious and life-threatening cases of viral reactivation have been reported, including Epstein-Barr virus and cytomegalovirus reactivation. FDA also notes that immunocompromised patients are at increased risk.
FDA lists common side effects including vomiting, rash, increased liver transaminases and headache. FDA safety materials also discuss infection risk, changes in white blood cell counts such as lymphopenia and neutropenia, cytokine release syndrome and hypersensitivity reactions.
Because this is an immune therapy, families should expect careful screening, monitoring and follow-up with a pediatric diabetes specialist or endocrinology team. The FDA prescribing information and Medication Guide should be reviewed with the treating clinician before treatment.
Practical takeaway for families
If a child has recently been diagnosed with Stage 3 type 1 diabetes, this approval may be worth discussing promptly with the child’s diabetes team. The trial enrolled children within six weeks of diagnosis, so timing may matter.
Useful questions include: Is my child in the group this approval applies to? How much insulin production remains? What screening is needed before treatment? What monitoring is needed during and after treatment? How would this fit with insulin, glucose monitoring, school routines and sick-day planning?
Do not stop or reduce insulin because of this news. Do not assume Tzield is right for every child with type 1 diabetes. Use this update as a reason to speak with a clinician who knows the child’s diagnosis, timing, labs and safety risks.
Sources
- U.S. Food and Drug Administration. FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes. Published June 15, 2026.
- U.S. Food and Drug Administration. FDA Approves Drug for Pediatric Stage 3 Type I Diabetes. Content accessed June 19, 2026.
Editorial and verification notes
This Living Diabetes article was written for general education from FDA source material. It was checked for indication wording, age range, Stage 3 meaning, accelerated approval language, C-peptide caveats, treatment-study details, safety warnings and patient-safety framing. It is not individualized medical advice.